

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Sep 5, 2021





RESPIRATORY PATHOGEN PANEL Sep 05, 2021 Positivity Rate (%)

MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Entero Rhino	ADENO	BOCA	Legio nella	Chla mydia	Myco plasma
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.7	13.5	0.0	1.3	6.2	0.1	0.1	0.1	0.5	0.0	0.6	14.1	1.3	3.9	0.0	0.0	0.0
SEP	0.0	0.0	0.0	0.0	0.0	0.1	2.0	2.2	0.0	0.1	0.2	0.1	0.0	0.0	0.1	0.0	0.1	2.1	0.1	0.5	0.6	0.0	0.0
OCT																							
NOV																							
DEC																							

Increased prevalence of viruses: **RSV (type B), Parainfluenza 3 and Rhinovirus.**



Parainfluenza 3 POSITIVITY RATE 2021 (%)





ACL RSV PCR by Cepheid - assay was started on Aug 8th 2021

CDC Data RSV pos rate for Region 5 Chicago - (PCR - 28%, Antigen - 41% ↑)




SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5
Aug 29	7.5	8.5	9.0	21.3	0	0	0	0	38.9	32.5	43.9	38.8
Aug 22	6.0	7.3	13.5	16.1	0	0	0	0	31.3	27.1	32.5	20.6
Aug 15	6.6	6.8	9.8	18.0	0	0	0	0	22.9	23.5	27.0	16.7
Aug 8	6.8	7.4	9.8	15.8	0	0	0	0	16.6	22.7	25.7	16.9
Aug 1	3.8	6.9	10.5	17.6	0	0	0	0	14.9	20.0	0.0	0.0
Jul 25	2.7	4.1	8.0	11.8	0	0	0	0	15.5	16.7	0.0	0.0
Jul 18	1.8	2.6	1.4	7.2	0	0	0	0	15.6	21.6	0.0	0.0
Jul 11	1.6	1.6	1.0	5.0	0	0	0	0	16.7	17.4	0.0	0.0
Jul 4	1.6	1.4	0.0	3.0	0	0	0	0	15.5	15.5	0.0	0.0
Jun 27	1.7	1.5	1.5	2.8	0	0	0	0	11.1	8.3	0.0	0.0


ACL RSV tests results are consistent with “atypical” summer RSV outbreak

ACL COVAG and SCVPCR - Pos rate (%) - Sep 05, 2021


- IL % COVAG
- WI % COVAG
- IL % SCVPCR
- WI % SCVPCR



Sep 1, 2021 - daily COVID-19 cases in US - CDC




Aug 28, 2021 – SARS-CoV-2 circulating in the US (~99.4% % Delta variants)



US vaccination status CDC | Data as of: Sep 2, 2021



372,116,617 Vaccines Administered	
205,911,640 People who received at least one dose	174,973,937 People who are fully vaccinated*
62% Percentage of the US population that has received at least one dose	52.7% Percentage of the US population that has been fully vaccinated*

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – August 28, 2021




2020-21 Influenza Season Week 34 ending Aug 28, 2021


ILI Activity Level



CSF targets positivity rate is 5.6% (*the most prevalent is VZV*)



The most prevalent GI bacterial target is (Cryptosporidium 1.0%)



The most prevalent GI viral target is – (Norovirus II – 0.2%)

